IQV
NYSE · Life Sciences Tools & Services
Iqvia Holdings Inc
$178.71
+0.07 (+0.04%)
Financial Highlights (FY 2026)
Revenue
15.95B
Net Income
1.33B
Gross Margin
33.3%
Profit Margin
8.3%
Rev Growth
+4.2%
D/E Ratio
2.45
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 33.3% | 33.3% | 49.9% | 49.9% |
| Operating Margin | 13.3% | 12.0% | 10.4% | 11.9% |
| Profit Margin | 8.3% | 7.9% | 10.4% | 8.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 15.95B | 15.31B | 16.41B | 12.85B |
| Gross Profit | 5.31B | 5.10B | 8.19B | 6.41B |
| Operating Income | 2.13B | 1.84B | 1.71B | 1.53B |
| Net Income | 1.33B | 1.15B | 1.71B | 1.05B |
| Gross Margin | 33.3% | 33.3% | 49.9% | 49.9% |
| Operating Margin | 13.3% | 12.0% | 10.4% | 11.9% |
| Profit Margin | 8.3% | 7.9% | 10.4% | 8.2% |
| Rev Growth | +4.2% | +4.2% | -4.8% | -8.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 9.78B | 9.78B | 12.85B | 14.01B |
| Total Equity | 3.99B | 3.99B | 15.35B | 15.53B |
| D/E Ratio | 2.45 | 2.45 | 0.84 | 0.90 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 3.34B | 3.05B | 2.36B | 1.78B |
| Free Cash Flow | — | — | 1.51B | 1.28B |